An FDA panel recently met to consider CoAxia's de novo application for use of its NeuroFlo catheter within 14 hours after symptoms begin to show in ischemic stroke patients who aren't fit to receive thrombectomy or tissue plasminogen activator. The device, which already has 510(k) clearance, is used to control or halt the flow of blood in peripheral vessels.